AnaptysBio Statistics
Total Valuation
AnaptysBio has a market cap or net worth of $580.10 million. The enterprise value is $660.84 million.
Important Dates
The last earnings date was Wednesday, August 6, 2025, after market close.
| Earnings Date | Aug 6, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
AnaptysBio has 28.00 million shares outstanding. The number of shares has increased by 10.75% in one year.
| Current Share Class | 28.00M |
| Shares Outstanding | 28.00M |
| Shares Change (YoY) | +10.75% |
| Shares Change (QoQ) | -5.98% |
| Owned by Insiders (%) | 2.96% |
| Owned by Institutions (%) | 88.73% |
| Float | 16.09M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 5.00 |
| Forward PS | 9.60 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 5.37 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 8.22
| Current Ratio | 8.22 |
| Quick Ratio | 8.08 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -1.22 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -14.12% |
| Return on Invested Capital (ROIC) | -15.59% |
| Return on Capital Employed (ROCE) | -28.74% |
| Revenue Per Employee | $905,618 |
| Profits Per Employee | -$974,956 |
| Employee Count | 136 |
| Asset Turnover | 0.32 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, AnaptysBio has paid $77,000 in taxes.
| Income Tax | 77,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -38.56% in the last 52 weeks. The beta is -0.19, so AnaptysBio's price volatility has been lower than the market average.
| Beta (5Y) | -0.19 |
| 52-Week Price Change | -38.56% |
| 50-Day Moving Average | 24.02 |
| 200-Day Moving Average | 20.16 |
| Relative Strength Index (RSI) | 32.77 |
| Average Volume (20 Days) | 517,599 |
Short Selling Information
The latest short interest is 9.56 million, so 34.16% of the outstanding shares have been sold short.
| Short Interest | 9.56M |
| Short Previous Month | 9.38M |
| Short % of Shares Out | 34.16% |
| Short % of Float | 59.43% |
| Short Ratio (days to cover) | 18.41 |
Income Statement
In the last 12 months, AnaptysBio had revenue of $123.16 million and -$132.59 million in losses. Loss per share was -$4.46.
| Revenue | 123.16M |
| Gross Profit | -40.64M |
| Operating Income | -86.14M |
| Pretax Income | -170.11M |
| Net Income | -132.59M |
| EBITDA | -85.56M |
| EBIT | -86.14M |
| Loss Per Share | -$4.46 |
Full Income StatementBalance Sheet
The company has $265.71 million in cash and $346.46 million in debt, giving a net cash position of -$80.75 million or -$2.88 per share.
| Cash & Cash Equivalents | 265.71M |
| Total Debt | 346.46M |
| Net Cash | -80.75M |
| Net Cash Per Share | -$2.88 |
| Equity (Book Value) | -44.73M |
| Book Value Per Share | -1.60 |
| Working Capital | 256.38M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$127.71 million and capital expenditures -$372,000, giving a free cash flow of -$128.08 million.
| Operating Cash Flow | -127.71M |
| Capital Expenditures | -372,000 |
| Free Cash Flow | -128.08M |
| FCF Per Share | -$4.57 |
Full Cash Flow StatementMargins
Gross margin is -33.00%, with operating and profit margins of -69.94% and -107.66%.
| Gross Margin | -33.00% |
| Operating Margin | -69.94% |
| Pretax Margin | -107.59% |
| Profit Margin | -107.66% |
| EBITDA Margin | -69.47% |
| EBIT Margin | -69.94% |
| FCF Margin | n/a |
Dividends & Yields
AnaptysBio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -10.75% |
| Shareholder Yield | -10.75% |
| Earnings Yield | -22.86% |
| FCF Yield | -22.08% |
Analyst Forecast
The average price target for AnaptysBio is $48.00, which is 131.49% higher than the current price. The consensus rating is "Buy".
| Price Target | $48.00 |
| Price Target Difference | 131.49% |
| Analyst Consensus | Buy |
| Analyst Count | 10 |
| Revenue Growth Forecast (5Y) | 11.87% |
| EPS Growth Forecast (5Y) | -1.50% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
AnaptysBio has an Altman Z-Score of -1.93 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -1.93 |
| Piotroski F-Score | 4 |